Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Biovie's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Biovie's regulatory disclosures and financial reporting.
BioVie Inc.'s President and CEO, Cuong Do, has filed a Schedule 13D reporting beneficial ownership of 399,018 shares of the company’s Class A common stock, representing 5.03% of the class. The filing aggregates shares, warrants and stock options held directly and through Do & Rickles Investments, LLC.
The percentage is based on 7,541,539 shares outstanding as of March 23, 2026, plus 388,119 shares issuable upon exercise of warrants and options exercisable within 60 days. The securities were acquired with personal funds and as equity compensation and are described as a long-term investment, though the reporting persons may buy or sell in the future.